Skip to main content

Table 3 Significant effect of clinical variables on clinical outcomes

From: Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients

Clinical variables Clinical outcomes P OR/HR (95% CI)
Risk stratifications OS (mean day ± SE) 0.027  
 Low + intermediate 1473 ± 82   1.00 (reference)
 High 1048 ± 113   2.325 (1.103–4.900)
Risk stratifications PFS (mean day ± SE) 0.013  
 Low 1532 ± 151   1.00 (reference)
 Intermediate 1096 ± 99 0.056 2.762 (0.974–7.834)
 High 740 ± 105 0.005 4.801 (1.606–14.350)
Platelets, ×109/L CR (%)   
 < 38.5 78.6   1.00 (reference)
 ≥ 38.5 92.2 0.006 3.225 (1.362–7.635)
Risk stratifications
 Liver function damage (%) 0.009  
 Low 22.9   1.00 (reference)
 Intermediate 5.9 0.008 0.213 (0.071–0.638)
 High 15.1 0.355 0.660 (0.202–1.784)
Risk stratifications Cardiotoxicity (%) 0.004  
 Low 17.1   1.00 (reference)
 Intermediate 2.5 0.005 0.126 (0.030–0.535)
 High 3.8 0.079 0.190 (0.036–1.001)
  1. CR complete remission, OS overall survival, RFS relapse-free survival, CI confidence interval, HR hazard ratio, OR odd risk, SE standard error